<SEC-DOCUMENT>0001396814-25-000011.txt : 20250110
<SEC-HEADER>0001396814-25-000011.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110080145
ACCESSION NUMBER:		0001396814-25-000011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pacira BioSciences, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				510619477
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35060
		FILM NUMBER:		25520509

	BUSINESS ADDRESS:	
		STREET 1:		5401 WEST KENNEDY BOULEVARD
		STREET 2:		SUITE 890
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33609
		BUSINESS PHONE:		813-553-6680

	MAIL ADDRESS:	
		STREET 1:		5401 WEST KENNEDY BOULEVARD
		STREET 2:		SUITE 890
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pacira Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20101029

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pcrx-20250110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1bf8ecee-9215-4d70-992d-c7ce0fc4af02,g:6171b111-b194-406e-a7a3-4ee63f060c75,d:4a43d9b9a5464d5198ad38aeada175e1-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pcrx-20250110</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-21">1/10/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001396814</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pcrx-20250110.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-10</xbrli:startDate><xbrli:endDate>2025-01-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4a43d9b9a5464d5198ad38aeada175e1_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#000000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:11pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">CURRENT REPORT</span></div><div style="padding-left:33.75pt;padding-right:33.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Pursuant to Section 13 or 15(d) of the</span></div><div style="padding-left:33.75pt;padding-right:33.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Securities Exchange Act of 1934</span></div><div style="margin-top:11pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">January 10, 2025</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">PACIRA BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:27.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-35060</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">51-0619477</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:108%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">5401 West Kennedy Boulevard, Suite 890</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:108%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Tampa</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Florida</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">33609</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(Address and Zip Code of Principal Executive Offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">813</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">553-6680</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:113%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:113%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:113%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:113%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.001%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">PCRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#000000;padding:0 1pt"/></tr></table></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4a43d9b9a5464d5198ad38aeada175e1_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item&#160;2.02. Results of Operations and Financial Condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2025, Pacira BioSciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 and Exhibit&#160;99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-2024revenuepressrelea.htm">Press Release dated January 10, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (Formatted as Inline XBRL)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4a43d9b9a5464d5198ad38aeada175e1_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%">SIGNATURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:5.351%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PACIRA BIOSCIENCES,&#160;INC.<br/>(REGISTRANT)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ KRISTEN WILLIAMS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristen Williams</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Administrative Officer and Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pcrx-2024revenuepressrelea.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i53d53426599446b98bbab644590857f3_1"></div><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><img alt="paciralogo2025a.jpg" src="paciralogo2025a.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR IMMEDIATE RELEASE</font></div><div style="text-align:right"><font style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NEWS RELEASE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">-- Company also reports preliminary unaudited 2024 revenue of $701.0 million --</font></div><div><font><br></font></div><div><font style="color:#808080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parsippany, NJ., Jan. 10, 2025 (GLOBE NEWSWIRE)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-- Pacira BioSciences, Inc. (Nasdaq&#58; PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth-oriented plan to accelerate its ongoing transition into an innovative biopharmaceutical organization and become a therapeutic area leader in musculoskeletal pain and adjacencies. In addition, the company reported preliminary unaudited total revenue of $701.0 million for the year ended December 31, 2024, compared with $675.0 million for the year ended December 31, 2023. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5x30 Path to growth and value creation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The company intends to achieve the following five objectives by 2030 (&#8220;5x30&#8221;)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Patients&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> More than three million patients treated per year</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Product revenue&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Double-digit compounded annual growth rate</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Profitability&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Five percentage point gross margin improvement over 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Pipeline&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Clinical pipeline expansion with five novel programs in development</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Partnerships&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Establishing five partnerships including pipeline and commercial agreements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;We enter 2025 with a sharp focus on growth, operational excellence and a clear mission to deliver innovative, non-opioid pain therapies to transform the lives of patients,&#8221; said Frank D. Lee, chief executive officer of Pacira BioSciences. &#8220;Looking ahead, I am energized to lead Pacira during this exciting new chapter as we advance our 5x30 plan to address unmet patient needs in musculoskeletal pain and adjacencies. With a best-in-class commercial portfolio that is producing significant cash flow, we believe we are well equipped to extend our leadership in non-opioid pain management and transform Pacira into an innovative biopharmaceutical organization with a robust pipeline to support sustainable growth and enhanced value creation.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preliminary Unaudited Fourth Quarter Revenue Highlights</font></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Fourth quarter EXPAREL net product sales of $147.7 million in 2024, compared with $143.9 million in 2023. Volume growth and a price increase in 2024 were partially offset by a shift in vial mix and discounting associated with the company&#8217;s new group purchasing organization, or GPO, partnerships.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Fourth quarter ZILRETTA net product sales of $33.1 million in 2024, compared with $28.7 million in 2023.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Fourth quarter iovera&#176; net product sales of $6.5 million in 2024, compared with $6.0 million in 2023.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was zero in the fourth quarter of 2024, compared with $2.6 million in the fourth quarter of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preliminary Unaudited Full-year Revenue Highlights</font></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Full-year EXPAREL net product sales of $549.0 million in 2024, compared with $538.1 million in 2023. Full-year net product sales were comprised of average daily volume growth of 4 percent. There were 249 selling days in 2024 and 250 selling days in 2023.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Full-year ZILRETTA net product sales of $118.1 million in 2024, compared with $111.1 million in 2023.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Full-year iovera&#176; net product sales of $22.8 million in 2024, compared with $19.7 million in 2023.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was $11.1 million in 2024, compared with $6.1 million in 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The financial information included in this press release is preliminary, unaudited, and subject to adjustment. It does not present all information necessary for an understanding of the company&#8217;s financial results for the fourth quarter or full year 2024. Pacira expects to report its complete financial results for the fourth quarter and full-year 2024, along with the company&#8217;s financial guidance, later in the first quarter of 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pacira today announced the granting of inducement awards on January 3, 2025 to eight new employees under Pacira&#8217;s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Four employees received stock options to purchase an aggregate of 20,300 shares of Pacira common stock and eight employees received restricted stock units for an aggregate of 30,400 shares of Pacira common stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient&#8217;s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $18.40 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on the first anniversary of January 2, 2025.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting of the equity awards is subject to the employee&#8217;s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Pacira</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments&#58; EXPAREL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management&#59; ZILRETTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain&#59; and iovera&#186;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About EXPAREL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(bupivacaine liposome injectable suspension)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults. The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. The product combines bupivacaine with multivesicular liposomes, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption&#59; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Important Safety Information about EXPAREL for Patients</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. In the study where EXPAREL was given to children, the most common side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and&#47;or loss of muscle movement. How much and how long the loss of feeling and&#47;or muscle movement depends on where and how much of EXPAREL was injected and may last for up to 5 days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound, for patients younger than 18 years old, for injection near a nerve, and&#47;or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">cardiovascular system&#59; may cause an allergic reaction&#59; may cause damage if injected into the joints&#59; and can cause a rare blood disorder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About ZILRETTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(triamcinolone acetonide extended-release injectable suspension)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On October 6, 2017, ZILRETTA was approved by the U.S. Food and Drug Administration as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis (OA)- related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide&#8212;a commonly administered, short-acting corticosteroid&#8212;with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase 3 trial on which the approval of ZILRETTA was based showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16. Learn more at www.zilretta.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indication and Select Important Safety Information for ZILRETTA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indication&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> ZILRETTA is indicated as an intra-articular injection for the management of OA pain of the knee. Limitation of Use&#58; The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contraindication&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Warnings and Precautions&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Intra-articular Use Only&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be considered safe for epidural or intrathecal administration.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Hypersensitivity reactions&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Joint infection and damage&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> A marked increase in joint pain, joint swelling, restricted motion, fever and malaise may suggest septic arthritis. If this occurs, conduct appropriate evaluation and if confirmed, institute appropriate antimicrobial treatment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverse Reactions&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The most commonly reported adverse reactions (incidence &#8805;1%) in clinical studies included sinusitis, cough, and contusions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Please see ZILRETTALabel.com for full Prescribing Information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About iovera&#176;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The iovera&#176; system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">osteoarthritis of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced pain and system relief beyond 150 days. When stimulation compatible components are used, the iovera&#176; system can also facilitate targeting nerve location by conducting electrical nerve stimulation from a compatible 3rd party nerve stimulator. The iovera&#176; system is not indicated for treatment of central nervous system tissue.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indication and Select Important Safety Information for iovera&#176;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indication&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> iovera&#176; applies freezing cold to peripheral nerve tissue to block and&#47;or relieve pain for up to 90 days. It should not be used to treat central nervous system tissue.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Important Safety Information</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#10625;&#160;&#160;&#160;&#160;Do not receive treatment with iovera&#176; if you experience hypersensitivity to cold or have open and&#47;or infected wounds near the treatment site. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#10625;&#160;&#160;&#160;&#160;You may experience bruising, swelling, inflammation and&#47;or redness, local pain and&#47;or tenderness, and altered feeling at the site of application. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#10625;&#160;&#160;&#160;&#160;In treatment area(s), you may experience damage to the skin, skin darkening or lightening, and dimples in the skin.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#10625;&#160;&#160;&#160;&#160;You may experience a temporary loss of your ability to use your muscles normally outside of the treatment area.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#10625;&#160;&#160;&#160;&#160;Talk to your doctor before receiving treatment with iovera&#176;. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Any statements in this press release about Pacira&#8217;s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;can&#8221; and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to &#8216;5x30&#8217;, our growth and business strategy, our future outlook, contributions of new executives, our intellectual property and patent terms, our future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (&#8220;NOPAIN&#8221;) Act and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others&#58; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur&#59; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations&#59; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera&#176;&#59; the rate and degree of </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">market acceptance of EXPAREL, ZILRETTA and iovera&#176;&#59; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera&#176; and our ability to serve those markets&#59; our plans to expand the use of EXPAREL, ZILRETTA and iovera&#176; to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera&#176;&#59; the commercial success of EXPAREL, ZILRETTA and iovera&#176;&#59; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s&#59; the related timing and success of European Medicines Agency Marketing Authorization Applications&#59; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (&#8220;pMVL&#8221;) drug delivery technology&#59; the approval of the commercialization of our products in other jurisdictions&#59; clinical trials in support of an existing or potential pMVL-based product&#59; our commercialization and marketing capabilities&#59; our ability to successfully complete capital projects&#59; the outcome of any litigation&#59; the ability to successfully integrate any future acquisitions into our existing business&#59; the recoverability of our deferred tax assets&#59; assumptions associated with contingent consideration payments&#59; assumptions used for estimated future cash flows associated with determining the fair value of the Company&#59; the anticipated funding or benefits of our share repurchase program&#59; and factors discussed in the &#8220;Risk Factors&#8221; of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the &#8220;SEC&#8221;). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">###</font></div><div style="text-indent:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:43.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Susan Mesco, (973) 451-4030</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">susan.mesco&#64;pacira.com</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Media Contact&#58;</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sara Marino, (973) 370-5430</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sara.marino&#64;pacira.com</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pcrx-20250110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1bf8ecee-9215-4d70-992d-c7ce0fc4af02,g:6171b111-b194-406e-a7a3-4ee63f060c75-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pcrx="http://www.pacira.com/20250110" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacira.com/20250110">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20250110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20250110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pacira.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>pcrx-20250110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1bf8ecee-9215-4d70-992d-c7ce0fc4af02,g:6171b111-b194-406e-a7a3-4ee63f060c75-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_d0499288-9f7e-4f53-b76b-1455f3665120_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9380ac51-8704-458f-b3f0-49eaa65e9582_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_15bcec5f-8a67-4caa-a511-631944083808_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bea8451b-292f-46f7-a4ff-4113aa28ab2e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d857b49c-856a-4552-a75b-e352cece420f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_376ae6aa-2a86-4056-9c73-8ff2141b4e2e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodStartDate_efe99d67-fdd2-454c-8d00-f0ef1867793c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodStartDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period Start Date</link:label>
    <link:label id="lab_dei_DocumentPeriodStartDate_label_en-US" xlink:label="lab_dei_DocumentPeriodStartDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period Start Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodStartDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodStartDate" xlink:to="lab_dei_DocumentPeriodStartDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ea6565c9-716c-4369-bd95-cc8f902194b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_bc739802-b014-44b5-9ffe-bc4d9b526738_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7298e65c-b54c-47fc-9103-9578a7ee460c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f5956f7f-cb7b-4441-8fae-c5351762f424_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3cded0fd-16ac-4c18-af48-2af1d971c7ff_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_af1df631-bf6a-4a98-b14b-8499cbfc7026_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_f37d49c6-4d59-4b8f-afe2-9a7f0cebec6f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c34d6b3a-05e4-469c-80d0-6c43813fe15a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6647d209-f60c-4f74-9cc1-8de25d199189_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_10bbedfe-42ec-45bc-b491-0a1ba7e7901c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_efbff99d-1b2a-419c-80e8-888842181538_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e008c9ae-de46-4e67-b40b-93b107a88429_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e674a413-11c4-40c0-9201-ef9e6b91f79a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7a327d49-b90b-4f8e-b2a1-8a219aab54fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_db838a28-86cf-42a8-b6b8-1264f8f9c798_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9afa3b62-1804-4d4f-ad7a-152363113285_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e708b452-28c9-47a4-9f08-917f1c15030e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>pcrx-20250110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1bf8ecee-9215-4d70-992d-c7ce0fc4af02,g:6171b111-b194-406e-a7a3-4ee63f060c75-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacira.com/role/CoverPage" xlink:type="simple" xlink:href="pcrx-20250110.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fc439465-008c-46f4-a412-906b38440cbd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_DocumentType_fc439465-008c-46f4-a412-906b38440cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1f3c3912-fada-4112-af90-764e4b1e4136" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_DocumentPeriodEndDate_1f3c3912-fada-4112-af90-764e4b1e4136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b737cc51-6c77-4034-958f-1cc6b2285d28" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityRegistrantName_b737cc51-6c77-4034-958f-1cc6b2285d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cecb18d1-8d20-45a0-b681-154a59013224" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cecb18d1-8d20-45a0-b681-154a59013224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_de42b63b-7cd0-4d9d-b334-1da04a3cb9c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityFileNumber_de42b63b-7cd0-4d9d-b334-1da04a3cb9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c83018ba-37d2-40b8-936e-8f5549cca691" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityTaxIdentificationNumber_c83018ba-37d2-40b8-936e-8f5549cca691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_484e592b-6b65-4ec3-98f4-cec3e9b90617" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityAddressAddressLine1_484e592b-6b65-4ec3-98f4-cec3e9b90617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3c7cdc37-347e-4a31-aa20-ef51c5d5c1a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityAddressCityOrTown_3c7cdc37-347e-4a31-aa20-ef51c5d5c1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5cdf5941-b2bc-4602-bd36-79ffcba62c24" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityAddressStateOrProvince_5cdf5941-b2bc-4602-bd36-79ffcba62c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c66dcdb2-eded-4ecb-9521-8b504f758a5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityAddressPostalZipCode_c66dcdb2-eded-4ecb-9521-8b504f758a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_623e160e-c2c8-4cbf-82de-ace560ccdece" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_CityAreaCode_623e160e-c2c8-4cbf-82de-ace560ccdece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2083a1a4-39e0-4164-affc-01a6201571f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_LocalPhoneNumber_2083a1a4-39e0-4164-affc-01a6201571f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f03047a7-2ed5-4d2f-86ff-4bede983d9b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_WrittenCommunications_f03047a7-2ed5-4d2f-86ff-4bede983d9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_cdc4779d-b027-4499-b903-846d88f36d21" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_SolicitingMaterial_cdc4779d-b027-4499-b903-846d88f36d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9a1525ec-457e-47c9-ac39-c21586bb93cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_PreCommencementTenderOffer_9a1525ec-457e-47c9-ac39-c21586bb93cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a95aa8c1-c447-42ad-82db-edde75d03571" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a95aa8c1-c447-42ad-82db-edde75d03571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a1af3946-fb9d-43a5-a45f-ffd6c3d28176" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_Security12bTitle_a1af3946-fb9d-43a5-a45f-ffd6c3d28176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0dcf3db1-ef53-4e4d-a45f-79a79fa206c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_TradingSymbol_0dcf3db1-ef53-4e4d-a45f-79a79fa206c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_79a2128b-3bdb-499e-82af-de8b02d09e72" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_SecurityExchangeName_79a2128b-3bdb-499e-82af-de8b02d09e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c7ad38c4-ad4d-4b64-ba59-1fe97fa1a9e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityEmergingGrowthCompany_c7ad38c4-ad4d-4b64-ba59-1fe97fa1a9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f51dde75-07ee-4b4b-9e8e-aa40f16623bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_EntityCentralIndexKey_f51dde75-07ee-4b4b-9e8e-aa40f16623bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d7cb5101-6982-4e6e-8b7c-70f422da1c10" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_AmendmentFlag_d7cb5101-6982-4e6e-8b7c-70f422da1c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodStartDate_65a504f8-bd02-458f-ba4c-a0537e21e94f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_99c3a1ad-bb2c-4570-9337-b774d84ba4a7" xlink:to="loc_dei_DocumentPeriodStartDate_65a504f8-bd02-458f-ba4c-a0537e21e94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>paciralogo2025a.jpg
<DESCRIPTION>PACIRA BIOSCIENCES LOGO
<TEXT>
begin 644 paciralogo2025a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+T17AI9@  34T *@    @ ! $[  (
M   .   !2H=I  0    !   !6)R=  $    <   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M061A;2!';VQD8F5R9P  !9 #  (    4   "II $  (    4   "NI*1  (
M   #-C   )*2  (    #-C   .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\T=F>OAL1[56EN7Z***X#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M5#5-=TG1(?-UG4[.P0CAKF=8\_3)YKB=5^.W@'2]RKJ[WTB_P6=N[_\ CQ 7
M]:VIT*M3X(M_(3DEN>BT5X;?_M0:-'G^S/#U]<>GVB9(<_EOKG;K]I_6G8_8
M_#UA$O82RO)C\MM=D<KQ<OLV^:(]K#N?2E%?+$_[2OC.7_56>CPC_9MY"?UD
M-4I?VA_'DGW;BQB_W+0?US6RR?$OM]Y/MHGUI17R/'^T'X_0_-?VDGLUHG]
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M]!5K*L7_ "_BA>U@?2-%?-+?M/Z]_#H&G#ZR2'^M1G]IWQ'_  Z)I8^OF?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6\_V#4CUL;I@&8_[#='_  Y]J[NO J4ITI<LU9FZ::N@HHHK,84444 %%%%
M!1110 4444 %%%% !1110 5YC\?=7U+1/AQ'=:/?W-A<&_C0RVTK1L5*OD9!
MZ5Z=7DO[2'_)+8O^PC%_Z"]=F!2>)@GW(G\+/F:Z\2:Y>Y^V:SJ%QGKYMT[9
M_,UFLQ9BS$DGJ2>M)17W:BELCA"BBBF 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% #D=HW#QL493D,IP170Z;\0O%^D8&G^)-3C5>D;7+.@_P"
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M ,*(4445S&X4444 %%%% !1110 5\Z_M1_\ (1\.?]<I_P":5]%5\Z_M1_\
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M6OH.BNFGF&*I[3?SU_,ATXOH?'.O?!'QUH6YVT@ZA"O_ "UT]_-S_P !X?\
M\=KA+FVGLYV@NX)()5^]'*A5A]0:_0&LK7?"^A^)K?R->TJUOD PIFC!9?HW
M4?@:].CG<UI5C?T,W170^#J*^D?%G[-.G7$3S^#M0DLYL9%K>-OC;V#_ 'E_
M'=7A7B;P;K_@^]^S>(--FM"3A)2-T<G^ZXX/\Z]O#XVAB/@>O;J8RA*.YAT4
M45V$!1110 5?T76]1\.ZO!J>C7<EI>6[;DD0_F".A!Z$'@U0HI-)JS ^S_A?
M\2+/XA^'A,1';ZK; +>VJGA3_?3/.P]O3H2<9/;U\'^&?$NI>$O$%OK&C3F*
MX@;D?PR+W1AW4_\ U^H!K[-\#>--.\=^&8=6TQMK?<N+<G+02#JI_F#W%?'Y
MC@'AY<\/A?X'93J<RL]SHZ***\@U"BBB@ HHHH **** "BBB@ KR7]I#_DEL
M7_81B_\ 07KUJN:\=>";+Q]H,>D:G<SV]NMPL[-;XWG:&& 2"!][T-=.%J1I
M5XSELF3)7BTCX>HKZZTS]G_P#IZCS["YU%AT>ZNGS^2;1^E==IO@?PKI!4Z;
MX=TRW=>DBVJ;_P#OHC/ZU]%/.J*^&+?X'.J,NI\3Z=H.L:P0-)TJ]OLG'^C6
M[R?^@@UU5C\&/B!J !B\.3Q*>]Q+'%C\&8']*^S    !@#H!17'/.ZK^""7X
M_P"1:HKJSY5L?V;O&ES@W4^EV8[B2X9F_P#'5(_6NBLOV7;AL'4?%$:>JP69
M;]2X_E7T117++-L5+9V^12I0/&;+]F7PM#@WVJZK<D=D:.-3^&TG]:W;7X!?
M#ZWQYFDS7)'>:\E_]E85Z317-+'8F6\W^17)%=#C[7X3>!+/'E>%[!L?\]4,
MO_H1-:D7@CPI!_J?#&CQ_P"[81#_ -EK<HK!UJLMY/[RN5=C/B\/Z-!_J=)L
M8_\ <MD']*LK8VB_=M81](Q4]%0Y2>[&,6&-?NQH/HHHDABE&)8T<>C*#3Z*
MFX%&70])F_UVEV<G^_;H?Z52F\%>%KD?Z1X:TB7_ '["(_\ LM;=%6JDULQ6
M1R4_PK\"W.?,\+::,_\ /.'9_P"@XK'O?@/\/KS)31GM6/\ %!=2C]"Q'Z5Z
M+16L<57CM-_>Q<L>QXQ??LR^%YLFPU75+9CT#M'(H_#:#^M<MJ7[+^J1Y.D>
M([.X]!=0-#^JEZ^D**Z89GBX?;OZDNG!]#Y U7X#^/M+4NFE1W\:]6LYU?\
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M-'+/ID(T74&R1+:K^Z8_[4?3\L&O6H9U&3M6C;S1E*B^A\CT5U7C;X=:_P"
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M HHHH *^=?VH_P#D(^'/^N4_\TKZ*KYU_:C_ .0CX<_ZY3_S2O3RK_>X_/\
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M>\9^;\@:\YFADMYFBGC>*1#AD=2"I]"#7K4ZU.JKTY7,FFMQE%%%:B"BBB@
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MW2"UBCAAC&$CC4*JCT '2I**^2KXFKB)<U1W.N,5%:!1117.4%%%% !1110
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M_(U4(K9#(H8H(Q'!&D:#HJ* !^ I]%%<984444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG7]J/_ )"/AS_KE/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_A,_&2W-]%NTK3"LUQD<2OGY(_Q(R?8'UK*M5C1INI+9#2;=D>N_ 7X<?\
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MSC)[7):#'_?P"OBRBN>>38=_"VBE6D??]G?VFHP";3[J"ZB/22"0.OYBIZ^
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M+_NKT7\ *RZ**]F,5%62L8A1113 **** "BBB@ HHHH **** "BBB@ HHHH
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M5VD?8"(L:*B *JC  ' %+117YZ>@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?'?BG_D<-9_Z_Y__1C5]B5\=^*?^1PUG_K_ )__
M $8U>[DWQS]$7$RJ***^D+"BBB@#Z-^ W_)/)?\ K_D_]!2O3*\S^ W_ "3R
M7_K_ )/_ $%*],KXG&_[S/U,GN%%%%<@@HHHH **** "BBB@ KYU_:C_ .0C
MX<_ZY3_S2OHJOG7]J/\ Y"/AS_KE/_-*]/*O][C\_P F95?@9X'1117VIQA1
M110!;TK3KC6-8M--LUW7%W,D,8_VF( _G7W7H&CP>'_#MAI%H (;*!(5(&-V
M!R?J3D_C7R7\#;:.Z^+^CK* ?+\R1<CH5C8BOL2OE\[JMU(T^B5SIHK1L***
M*^?.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKA/'_Q;\/^ XV@GD^W:IMREC PW#TWMT0?7GVK2G2G5ERP5V)M)79W
M$LT=O"TL\BQ1H,L[L %'J2>E>5>,?V@O#/A_S+;0LZY>KD9A;; I]W[_ / 0
M?K7S_P"-_B7XB\=W1.K77E6:G]W8P$K$@SQD?Q'W.?PKD:^CPV317O5W?R1S
MRK/[)W7BOXP^,/%OF176I-96;\?9++,28]"?O-^)KA:**]VG2A27+!61@VWN
M%%%%:""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z;PU\0_%7A)
ME&B:Q<10K_R[R-YD1_X V0/PP:]E\*_M,6TOEV_C'2V@;H;NQ^9?J8R<C\"?
MI7SI17'7P5"O\<=>_4N,Y1V/O+0?$VC>*+$7F@:C!?0]S$WS)[,IY4^Q K4K
MX&TK6-1T._2]T>]GLKE.DL#E3]..H]J]S\"_M(,GEV7CNWWCH-1MDY'N\8Z_
M5?RKY_$Y/4I^]2]Y?C_P3>-9/<^AJ*IZ5J^GZYIT=_I%Y#>6LGW987# ^WL?
M:KE>(TT[,W"N5^)UBNH?"SQ' W\.GRRCZQKO'ZK755C^+X_.\$:Y%_?TZX7\
MXVK2B^6I%^:$]CX1HHHK]#//"BBB@ K[)^"-P;GX-:"S')5)8S[;9G _0"OC
M:OKK]GY]_P '[ ?W)YU_\B$_UKQ,Z5\.GY_HS:C\1Z91117R1UA1110 4444
M %%%% !1110!^?-%%%?I!YP4444 %?6G[/'_ "26#_K\F_F*^2Z^M/V>/^22
MP?\ 7Y-_,5XV<_[M\U^IM1^(]2HHHKY ZPHHHH **** "BBB@ HHHH ****
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MCOQ3_P CAK/_ %_S_P#HQJ]W)OCGZ(N)E4445](6%%%% 'T;\!O^2>2_]?\
M)_Z"E>F5YG\!O^2>2_\ 7_)_Z"E>F5\3C?\ >9^ID]PHHHKD$%%%% !1110
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M(RAE*L 0>"".M;1SR?VH+[R?8+N?GU17W3J/@?PMJX/]I>'=,N&/5VM4W?\
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M2JPK04X.Z9QM-.S"BBBM1!1110!9T_\ Y"5K_P!=D_F*^_:^ M/_ .0E:_\
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M (;33[$++=28>[NRN&G?^BCD =N>Y)/ ?L\>!(]*\.'Q3?Q9OM1!6VW#_50
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^._%/_(X:S_U_P __HQJ^Q*\\OO@GX6U#4+B\N)-0\VXE:5]
MLZ@;F))Q\OJ:]3+L53P\I.?4J+L?--%?1_\ PH?PC_STU+_P(7_XFC_A0_A'
M_GIJ7_@0O_Q->Q_:V&\_N*YD?.%%?1__  H?PC_STU+_ ,"%_P#B:/\ A0_A
M'_GIJ7_@0O\ \31_:V&\_N#F0WX#?\D\E_Z_Y/\ T%*],K%\*^%=/\'Z2^G:
M2T[0-,9OW[AB"0 >0!Q\M;5?-XFI&I6E..S9#W"BBBN<04444 %%%% !1110
M 5\Z_M1_\A'PY_URG_FE?15?.O[4?_(1\.?]<I_YI7IY5_O<?G^3,JOP,\#H
MHHK[4XPHHHH ]'^ O_)8M+_ZYS?^BFKZ_KY ^ O_ "6+2_\ KG-_Z*:OK^OD
M<Z_WA>GZLZZ/PA1117BFP4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!Y[\<]6.D_"+5=C;9+PQVJ>^YAN'_? :OCNOIS]IRXV^!])ML_ZS
M4=^/]V-Q_P"S5\QU]AD\%'#7[MG)6?O!1117L&(5J^&-';Q!XKTO2%S_ *;=
M1PL5ZA2P!/X#)_"LJO3?V?M/2^^+EG)(,_8[>:<#WV[!_P"AUAB*GLJ,I]DQ
MQ5VD?6EI:PV-G#:6L8C@@C6.-!T55& /R%2T45^?;GH!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\V?M ?
M#2+2;C_A+=#MQ':W,FV_B0<1R$\2 =@QX/O]:^DZJZGIMKK&EW.G:C"LUK=1
MM%+&PZJ1BNO"8F6&JJ:VZ^A$XJ2L? =%%%?>G"%%%% !7U)^S-_R334/^PO)
M_P"B8:^6Z^I/V9O^2::A_P!A>3_T3#7DYO\ [J_5&M'XCV*BBBOC3L"BBB@
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M^(]-HHHKY$ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\E_:0_Y);%_P!A&+_T%Z]:KR#]I2Z@C^&UK;22
MJLTVH(T<9/+!5?<1],C\Q7;@/]ZAZD5/A9\L4445]V<(4444 6=/_P"0E:_]
M=D_F*^_:^ M/_P"0E:_]=D_F*^_:^:SS>G\_T.FAU"BBBOG#H"BBB@ HHHH
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M=32^79W3?9+HD\;'( )^C;3^%<./HNMAI16^_P!Q=-VDF?9U%%%?"G<%%%%
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M**** "BBB@ HHHH *^=?VH_^0CX<_P"N4_\ -*^BJ^=?VH_^0CX<_P"N4_\
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M)^'^GM&62\UB1,V]DK=,]&?^ZOZGMZC@OB)^T/;VT<VF>!,3SD%6U)U^1/\
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M.O6Z^$Q_^]3]3NI_"@HHHKB+"BBB@ HHHH **** "OG7]J/_ )"/AS_KE/\
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M4=%20PR7$Z0PH7DD8*BCJ2>@KZ+8YR.BBB@ HHHH *^I/V9O^2:ZA_V%Y/\
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MA!]>C_CS[UXY16%;#TJ\>6HKCC)QV/N#PK\0_#'C*('0]4BDGQEK64[)E_X
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M 5X5;)J\-:;4OP?]?,W5:+W/IJBO)]%_:+\%ZEM74OMNDR'J9X?,3/L4R?S
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M HHHH *^=?VH_P#D(^'/^N4_\TKZ*KYU_:C_ .0CX<_ZY3_S2O3RK_>X_/\
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MUX5CR+/2M6G/JZ1H#_X^3^E?+]%6LGPJ[_>+VTCZ%N_VHT&18^%6/HTU]C]
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M7M937I49R=1VN8U8N25CP>BO:?\ AF/Q1_T&=(_[ZE_^(H_X9C\4?]!G2/\
MOJ7_ .(KZ#^T,+_.CG]G+L>+45[3_P ,Q^*/^@SI'_?4O_Q%'_#,?BC_ *#.
MD?\ ?4O_ ,11_:&%_G0>SEV/0OV;?^273_\ 82E_] CKUNN(^$_@F_\  /@^
M72-4N+:XF:[>=7MBQ7:RJ,?,!SE37;U\?C)QGB)RB[IL[(*T4F%%%%<I0444
M4 %%%% !1110 5\Z_M1_\A'PY_URG_FE?15>8?&'X67_ ,16TN72[^VM9;+S
M%9;@-AE;!R"H/(V],=Z[\OJPI8F,YNRU_(SJ)N-D?)%%>U_\,Q>)?^@UI7YR
M?_$T?\,Q>)?^@UI7YR?_ !-?5?VCA?YT<OLY]CQ2BO:_^&8O$O\ T&M*_.3_
M .)H_P"&8O$O_0:TK\Y/_B:/[1PO\Z#V<^QS?P%_Y+%I?_7.;_T4U?7]>'_#
M7X&:SX+\=6NN:CJMA-!;I(/+@#EF+*5[@ #G.:]PKYO-*U.M74J;NK?YG32B
MU'4****\HU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /+O'GP)\/>+&DO=+QHVIMR9(4S%*?]I/7W&/QKYW\8_#/Q
M-X(E8ZO8,]IG"WMOEX6_'^'Z-@U]LTV6*.:)HID62-QAD<9##T(KU<+FE:A[
MLO>7G_F92I1D?GW17UYXI^!'@WQ&9)K6U;1[MN?-L<*A/O&?E_+%>.>)/V=_
M%VD,\FCFWUJW7D>2WERX]T8X_(FOH*&:8:KHWROS.>5*2/)J*NZGH^I:+=&V
MU>PN;&8'[EQ$R$_F.:I5Z2::NC,****8!1110 4444 %%%% !1110 4444 %
M%%* 2<#DT )177>'_A=XR\3,ITW0KE86_P"6]RODQX]<MC/X9KU3PY^S&V4E
M\5ZV ."UM8)GZCS&_P#B:XZV.P]'XY:_>6H2>R/ (H9+B98H(WED<X5$4DL?
M0 5ZAX0^ /BKQ%LGU9%T.R;!W7*YE8>T?4?\"(KZ2\,> _#7@^(+H&E06\F,
M-<$;Y6^KGG\.E=#7AXC.I/2BK>;-HT5U.(\%?";POX(5)K*T^UZ@!S?70#R
M_P"R.B?AS[FNWHHKPZE2=67--W9NDEH@HHHK,84444 %>(?M"?#IM6TX>+=(
MAW7=E'MO47K)".C^Y7O[?2O;Z1T61&210RL,,K#((]*Z,/7EAZJJ1Z$RBI*S
M/SZHKZ%\6_LV7%]XCN+KPIJ%G9Z?,=ZVUQOS$QZJN ?E]/3IVS6+_P ,Q^)?
M^@UI/YR?_$U]A',L+**?/8Y/9R['BE%>U_\ #,?B7_H-:3^<G_Q-'_#,?B7_
M *#6D_G)_P#$T_[1PO\ .A>SEV//_ASXVN? ?C"WU2'<]JW[J[A!_P!9$3S^
M(ZCW%?:6G:A::MIMO?Z=.EQ:W""2*5#D,IKYM_X9C\2_]!K2?SD_^)KU#X3^
M!?%?P_CGTW5-2L+_ $B4F1(XGDWP/W*Y7&#W''//KGQLSEAJZ]I3FN9?B;4^
M:.C1Z77%?$OX<6?Q!T1(S(+35+0E[*\ ^X?[K8YVG ]P<$>A[6BO#IU)4IJ<
M'9HW:35F>&Z'\7=<\!WR>'/BUI]PK1C;!JL2[_-4<;F_OC_:7GU&<UZQI'C'
MPWKT:OH^N6%WN&0D<Z[Q]5SN'T(J[JNC:;KMBUGK-C;WULW)BN(PZY]1GH?>
MO-]4_9U\#ZA*TEH-0TW/.RVN-R_E(&/ZUV.>%K:S3@_+5?=T(M*.VIZHS!5)
M8@ =2>U<YKOQ#\)^&X)'U77K*-XQS!'*))3[!%RWZ5YR/V9M!+!)/$&K- .D
M8\L8_'&/TK=T;]G_ ,"Z3*LL]I=:FZG(^VSY7/\ NH%!^A!I>SP<=74;]%;\
MV%Y]CC-7\9>+/C5<RZ!X$L9=,T G9>:A<?*77N&(X /]Q<D]SC->O^"/!>F^
M!/#<6DZ4"V#OGN&&'GD/5C_(#L *V[2SMM/M([6PMXK:WC&$AA0(B#T ' J:
MHK8GGC[.FN6/;OYL<8V=WN?GS1117WAPA1110 5]B_ K_DBNA?\ ;Q_Z425\
M=5]B_ K_ )(KH7_;Q_Z425XF=?[O'U_1FU'XCT&BBBODCK"BBB@ HHHH ***
M* "D=%D0I(H96&"K#((I:* ..UOX3>"/$!9[[P_:QRM_RUM08&SZG81G\<UP
M6K_LQZ%<;FT36[ZR8]%N$6=1^6T_J:]NHKKIXW$4OAF_S_,APB]T?,5_^S+X
MGAR=/U?2[H#M(9(F/X;2/UKG;OX"?$*V)\O1XKE1_%#>1?R9@?TKZ_HKMCG&
M)CO9_+_(CV,3XIN/A1X[M3B3POJ#?]<H_,_]!)JHWPY\:)U\)ZS^%C(?Y"ON
M&BMEG=7K%?B+V*[GP]'\.?&DOW?">LC_ 'K&1?YBK<7PG\=R_=\+WX_WT"_S
M-?:U%#SNKTBOQ#V*[GQU:? WXA7;<: 85[M-<Q+C\-V?TK?LOV:_&-Q@W=YI
M5HO<-,[L/P"8_6OJ:BLI9SB7M9?(?L8GS]IG[+RA@VL^)25[QVEM@_\ ?3-_
M[+7:Z3\ / >F;6GL;G4G7^*\N"?T3:/TKTRBN2IF&*J;S?RT_(M4XKH9VD>'
MM&T"'RM$TNTL$(P?L\*H6^I R?QK1HHKB<G)W984444@"BBB@ HHHH ****
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MC_P!>P\SX77PWKC?=T;4#]+5_P#"I%\)^(W^YH&J-]+*0_TK[N50BA4 55&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW+ABO.,CM715PM:C'FJ1LB5*+V-BBBBN8H***\6?]IKPTDC*=%U7*DCI'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO7H:^R;"_MM4T^WOK"99[:XC$D4J'AE(R#7SN.P4L+/O%[,Z(3YD6*P/'O\
MR3?Q+_V";K_T2U;]8'CW_DF_B7_L$W7_ *):N.E_$CZHM['PQ7V9\%O^2.:!
M_P!<I/\ T:]?&=?9GP6_Y(YH'_7*3_T:]?49W_ CZ_HSEH_$=U1117R9UA7Y
M^S_\?,O^^?YU^@5?G[/_ ,?,O^^?YU]'D>]3Y?J<]?H:.F>%O$&M6IN='T+4
MM0@5RAEM;.250P )&5!&>1Q[U<_X0#QE_P!"EKO_ (+9O_B:^A_V:O\ DF%U
M_P!A27_T7'7KU:8C-IT:TJ:BM!1I)J]SX:_X0#QE_P!"EKO_ (+9O_B:/^$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/^^V7CT!K[#KT,YQ35J$?5_H9T8_:"BBBOFSI"BBB@ HHHH **** /$_C_\
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M;JQ)R37OY+04IRJOIHC"M+2QT7P_\&7/COQA;:/;$QQ'][=3 ?ZJ($;F^O(
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M>7,LD8#;6*G@L#U!'X5]UB:="<5[>UO-V.&+DG[IZ1_PU!K/_0O6/_?YZ/\
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M_?U1_6OD.OK<EM]7?K^B.2M\1]O?#2S6P^%WAR%!C.G0R$#U=0Y_5C745@>
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M5';_ /'M%_N#^525\@]SK,[7M!T[Q+HMQI6LVRW-I<+AT;J#V8'L1U!KX_\
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M +!D7_HR2O5R?_>ODS&M\)2_9Z_Y*Y:_]>L__H-?6U?)/[/7_)7+7_KUG_\
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MO_BJ/^%+_$'_ *%J?_O]%_\ %4?4\M[K_P "_P""'/4/6O\ AJ#1O^A=OO\
MO\E'_#4&C?\ 0NWW_?Y*\E_X4O\ $'_H6I_^_P!%_P#%4?\ "E_B#_T+4_\
MW^B_^*H^IY;W7_@7_!#GJ'V6C;T5O49I:;&"L2 ]0H!IU?)G4%%%% '(>/OA
MMH?Q!T]8]30P7L0Q;WT('F1^Q_O+['\,'FOFKQA\%?%WA)I)A9G5;!>1=6*E
M\#_:3[R^_!'O7V)17HX7,*V&7*M5V9G*FI'Y^(\D$H>-FCD0Y#*<%372Z?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCF@?]<I/_1KU]1G?\"/K^C.6C\1W5%%%?)G6%?G[/_Q\R_[Y_G7Z!5^?L_\
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M7_HR2O)RF+CB^62LTF:U=8%+]GK_ )*Y:_\ 7K/_ .@U];5\D_L]?\E<M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9^)/_)+_ !+_ -@R
M?_T UTU<S\2?^27^)?\ L&3_ /H!K6C_ !8^J%+9GP_7V)\"?^2*Z%_V\?\
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MA_B7_H7=6_\  &3_ .)K[MHKT?[<G_(OO,_8+N?"7_"'^)?^A=U;_P  9/\
MXFC_ (0_Q+_T+NK?^ ,G_P 37W;11_;D_P"1?>'L%W/A+_A#_$O_ $+NK?\
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M_#'QAXFE4:9H5T(F/_'Q<)Y,0'KN; /X9-?9>GZ#H^D_\@K2K&R_Z]K9(_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45881055388976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PACIRA BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0619477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5401 West Kennedy Boulevard, Suite 890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tampa<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">553-6680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001396814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M/;34J];@XY[^JK@Q3,#$I&DN#A:B:ZEPH25--,.0JE;@XW8]EPF/N.%B1;Y
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M9)7S![AICV%]QL4:O4_HJI8'%S@Y2>[1)M-NV+]0FQ9-$K8$(>_J&GQ;[??
M^X&16;'O7$@#N]CB=,TH&(9] .XOI30? [N5+?\3,?H/4$L#!!0    ( #5
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  U0"I:!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( #5 *EIH)JSH[0   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #5 *EJ97)PC$ 8  )PG   3
M          "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M-4 J6@_D #U:!   E1   !@              ("!# @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #5 *EJ?H!OPL0(  .(,   -
M          "  9P,  !X;"]S='EL97,N>&UL4$L! A0#%     @ -4 J6I>*
MNQS     $P(   L              ( !> \  %]R96QS+RYR96QS4$L! A0#
M%     @ -4 J6AE%%?4W 0  )P(   \              ( !81   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( #5 *EHD'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( #5 *EIED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pcrx-20250110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="pcrx-20250110.htm">pcrx-20250110.htm</File>
    <File>pcrx-20250110.xsd</File>
    <File>pcrx-20250110_lab.xml</File>
    <File>pcrx-20250110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pcrx-20250110.htm": {
   "nsprefix": "pcrx",
   "nsuri": "http://www.pacira.com/20250110",
   "dts": {
    "inline": {
     "local": [
      "pcrx-20250110.htm"
     ]
    },
    "schema": {
     "local": [
      "pcrx-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pcrx-20250110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcrx-20250110_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.pacira.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20250110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pcrx-20250110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period Start Date",
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.pacira.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001396814-25-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001396814-25-000011-xbrl.zip
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M2RGB[8&O4E0J14/&Z!SOW$P3:;Z'6LR*HK,TO/=MR(E"^PG=8),)EZ=F&*4
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MY/4U)J=+# FXB7@'^L,]8J,S[]CE, =V39'!1](VQ%O16M '5:[CTLK$IQ0
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M3)BEKY\^]MP1&U-MF1V/W?92M.4RA!=(B9TW7%F913'AZP&-TW$;/@5]+;!
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M<&,)TL+M%%-7%T06+Z=D#Q]8A;!T,S0*4YMJ".93+']8N2MZ*T"U[L9M%SH
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M/AK[*7T><[.[60V% + 5T$379D\LM?/C9R>0+'[.RLD0N (="BSK(SE692:
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M5IWZ(+!$-B!?N.]S.HX/7O8')UXU8H-+F,W=)K<;<38D9QZD(PK"SGV3(#T
M!  LF 0_]KW5@H>7YY72#\6KK\LW_P]02P,$%     @ -D J6HOD O)C @
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MW(G&N/^' <YL=#O.T':=SU.>EDKJOZNVM$CI?"K]*,&$AX"3@ !FL50E4WA
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MX3(@/D-N1"M]&/9L6PCCM&MK4*=&=12L:9^VG1?=%FT 6ZON3)^H15O60V9
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M<NMF,D!I6PY'%EDWG5U]]=CU2:N9<27&[^]>;>Y)5]^1^^[5_P!02P,$%
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M*5'H'(G"U,=B\NM!)9X*G/WV*9$7%G03RH +EWNE^- 3"K@[G!0?&+>W>5W
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M,3$P+FAT;5!+ 0(4 Q0    ( #9 *EJ+Y +R8P(    '   1
M  "  08O  !P8W)X+3(P,C4P,3$P+GAS9%!+ 0(4 Q0    ( #9 *EJH)7K-
M>0H  /-8   5              "  9@Q  !P8W)X+3(P,C4P,3$P7VQA8BYX
M;6Q02P$"% ,4    "  V0"I:"4OPQM\&  #Z,@  %0              @ %$
M/   <&-R>"TR,#(U,#$Q,%]P<F4N>&UL4$L%!@     %  4 4 $  %9#
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>pcrx-20250110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pcrx-20250110.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001396814</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">PACIRA BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-35060</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">51-0619477</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">5401 West Kennedy Boulevard, Suite 890</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Tampa</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">33609</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">813</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">553-6680</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">PCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
